MUMBAI, April 23 (Reuters) - Indian biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its $600 million research and development arm, Syngene, it said on Thursday.
The company plans to sell 22 million shares, including an overallotment, it said in a statement, after the prospectus was filed with India's market regulator.
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal15
12:02 Bank of America tops earnings forecast, predicts 'significant increase' in net interest income20
13:48 Wells Fargo Profit Falls 5.4% as Mortgage Revenue Declines22
13:21 Bank of America profits surge on cost cuts, trading gains23